e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

153.44 -0.81 (-0.53%)

Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

55 56 Next >

New research project aims to set standardized approach to lipoprotein(a) management

March 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

How Is The Market Feeling About Novartis? ↗

March 21, 2023

Via Benzinga

2 Biotech Stocks That Could Make You Richer ↗

March 21, 2023

One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.

Via The Motley Fool

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years ↗

March 20, 2023

Via Benzinga

FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations ↗

March 17, 2023

Via Benzinga

This High-Yielding Blue Chip Stock Is a Strong Buy ↗

February 13, 2023

This big pharma company pays a market-topping dividend to shareholders.

Via The Motley Fool

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories ↗

March 16, 2023

Benzinga

Via Benzinga

Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues ↗

March 16, 2023

Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues. Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane...

Via Benzinga

Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb

March 14, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...

Via FinancialNewsMedia

3 High Dividend Stocks With Attractive Total Return Potential ↗

March 10, 2023

In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.

Via InvestorPlace

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

March 08, 2023

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

Via News Direct

Topics Economy

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

March 08, 2023

By David Willey, Benzinga

Via TheNewswire.com

Topics Economy

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? ↗

March 07, 2023

Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.

Via Benzinga

4 AI Stocks That Are Revolutionizing Healthcare ↗

March 06, 2023

With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.

Via InvestorPlace

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? ↗

March 03, 2023

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗

February 24, 2023

Via Benzinga

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

Lupus Therapeutics Market Is on the Verge of Crossing at High CAGR of 9% in 2022-2029

February 21, 2023

The global lupus therapeutics market is expected to reach a CAGR of 9% during the forecast period (2022-2029).

Via SBWire

Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029

February 20, 2023

Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029).

Via SBWire

Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029

February 16, 2023

Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...

Via SBWire

Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029

February 16, 2023

Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029).

Via SBWire

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path ↗

February 14, 2023

Via Benzinga

Water for Injection Market Trends Outlook Demand 2023 -2030

February 13, 2023

Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International...

Via SBWire

Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?

February 10, 2023

Enterprise software maker Snowflake notched a three-month gain of 28.85%, far outpacing the S&P 500’s return of 9.32%. Analysts expect the price to rise 19%.

Via MarketBeat

Topics Stocks

Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030

February 09, 2023

The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)

Via SBWire

Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi

February 07, 2023

Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Topics Death

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy